InvestorsObserver
×
News Home

Should You Accumulate Neximmune Inc (NEXI) in Biotechnology Industry?

Friday, December 01, 2023 10:18 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Accumulate Neximmune Inc (NEXI) in Biotechnology Industry?

Neximmune Inc (NEXI) is near the middle in its industry group according to InvestorsObserver. NEXI gets an overall rating of 44. That means it scores higher than 44 percent of stocks. Neximmune Inc gets a 49 rank in the Biotechnology industry. Biotechnology is number 46 out of 148 industries.

Overall Score - 44
NEXI has an Overall Score of 44. Find out what this means to you and get the rest of the rankings on NEXI!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 44 means the stock is more attractive than 44 percent of stocks.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Neximmune Inc Stock Today?

Neximmune Inc (NEXI) stock is unmoved 0% while the S&P 500 is down -0.09% as of 3:58 PM on Thursday, Nov 30. NEXI is unchanged $0.00 from the previous closing price of $2.47 on volume of 5,774,658 shares. Over the past year the S&P 500 has risen 11.95% while NEXI is down -77.34%. NEXI lost -$42.01 per share the over the last 12 months. Click Here to get the full Stock Report for Neximmune Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App